This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pardillo, F. E. F.
Right arrow Articles by Gelber, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pardillo, F. E. F.
Right arrow Articles by Gelber, R. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2008, p. 3113-3117, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.01162-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Powerful Bactericidal Activity of Moxifloxacin in Human Leprosy{triangledown}

Fe Eleanor F. Pardillo, Jasmin Burgos, Tranquilino T. Fajardo, Eduardo Dela Cruz, Rodolfo M. Abalos, Rose Maria D. Paredes, Cora Evelyn S. Andaya, and Robert H. Gelber*

Leonard Wood Memorial Center for Leprosy Research, Cebu, Philippines

Received 3 September 2007/ Returned for modification 1 October 2007/ Accepted 9 June 2008

In a clinical trial of moxifloxacin in eight multibacillary leprosy patients, moxifloxacin proved highly effective. In all trial patients, a single 400-mg dose of moxifloxacin resulted in significant killing (P ≤ 0.006) of Mycobacterium leprae, ranging from 82% to 99%, with a mean of 91%. In all instances, no viable bacilli were detected with an additional 3 weeks of daily therapy, this observed rapid bactericidal activity being matched previously only by rifampin. On moxifloxacin therapy, skin lesions cleared exceedingly rapidly with definite improvement observed consistently after eight doses and progressive resolution continuing for the 56 days of the trial. Side effects, toxicities, and laboratory abnormalities were mild, not requiring discontinuation of therapy.

* Corresponding author. Present address: Leonard Wood Memorial Research Unit, 220 Scenic Avenue, San Anselmo, CA 94960. Phone: (415) 454-8765. Fax: (415) 454-8191. E-mail: ikgelber{at}hotmail.com

{triangledown} Published ahead of print on 23 June 2008.

Antimicrobial Agents and Chemotherapy, September 2008, p. 3113-3117, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.01162-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Gelber, R., Andries, K., Paredes, R. M. D., Andaya, C. E. S., Burgos, J. (2009). The Diarylquinoline R207910 Is Bactericidal against Mycobacterium leprae in Mice at Low Dose and Administered Intermittently. Antimicrob. Agents Chemother. 53: 3989-3991 [Abstract] [Full Text]  
  • Fajardo, T. T., Villahermosa, L., Pardillo, F. E. F., Abalos, R. M., Burgos, J., Dela Cruz, E., Gelber, R. H. (2009). A Comparative Clinical Trial in Multibacillary Leprosy with Long-Term Relapse Rates of Four Different Multidrug Regimens. Am J Trop Med Hyg 81: 330-334 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»